David Allison, Ph.D.

Westlake Village BioPartners  |   Director

David Allison, Ph.D. is a Managing Director at Westlake Village BioPartners. Prior to Westlake he was a Partner at 5AM Ventures since 2016 where he was involved in the firm’s investments in CinCor Pharma (acquired by AstraZeneca), Crinetics (NASDAQ: CRNX), Impel Neuropharma (NASDAQ: IMPL), Inipharm, Magnetic Insight, Neurogastrx, Portal Instruments, and Radionetics. Prior to 5AM Ventures, David held positions on the investment teams of Versant Ventures, Split Rock Partners and PTV Healthcare Capital.

Dr. Allison received a Ph.D. in Bioengineering from Rice University with a focus on the extracellular matrix in cardiovascular disease. He received a B.S.E in Biomedical Engineering from The University of Iowa.